Clinical Trial Update: Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for emricasan, a caspase inhibitor, in subjects with decompensated cirrhosis due to non-alcoholic steatohepatitis (NASH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Cirrhosis
• Non-alcoholic Steatohepatitis

Drugs mentioned

• Emricasan (emricasan)

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Decompensated Cirrhosis | Phase 2 | Status: UNKNOWN